CHICAGO — Combining brentuximab vedotin with a chemotherapy regimen as first-line therapy conferred an objective response in 88% of younger patients with newly diagnosed advanced-stage classical Hodgkin lymphoma, study results show.
Data from the phase 1/phase 2 study presented at ASCO Annual Meeting suggest that the regimen — already FDA-approved for the same indication as first-line therapy in adults — is safe and effective for younger patients, as well.
The cure rates for younger patients with Hodgkin lymphoma are typically higher than other pediatric cancers, with OS rates